PetMed Express (PETS) grants director James LaCamp 55,555 restricted shares

Q: What did PetMed Express (PETS) director James LaCamp report in this Form 4?

Director James LaCamp 55,555-share90,421 shares</b. after the grant, according to the Form 4 filing.

Q: Was the PetMed Express (PETS) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant/award acquisition 55,555 restricted shares$0.00 per share</b., consistent with a compensatory equity award.

Q: When do James LaCamp’s new restricted shares in PetMed Express (PETS) vest?

The 55,555 restricted shares August 11, 2027</b., subject to his continued service on the PetMed Express Board of Directors through that date.

Q: Under which plan was the PetMed Express (PETS) equity award to James LaCamp granted?

The 55,555-share restricted stock award PetMed Express, Inc. 2024 Omnibus Incentive Plan</b., which governs the terms and vesting conditions of the equity grant.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

LaCamp James reported acquisition or exercise transactions in this Form 4 filing.

PetMed Express IncJames LaCamp55,555 sharesAugust 11, 202790,421 shares

Positive

None.

Negative

None.

Insider Trade Summary

Net Buyer: 55,555 shares

Net Buy 1 txn

Insider LaCamp James

Role Director

Type Security Shares Price Value

Grant/Award Common Stock ^F1 55,555 $0.00 $0.00

Holdings After Transaction: Common Stock — 90,421 shares (Direct)

Footnotes (1)

F1. Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on August 11, 2027, subject to continued service on the Board of Directors.

Key Figures

Restricted stock award: 55,555 shares Transaction price per share: $0.00 per share Holdings after transaction: 90,421 shares +2 more

5 metrics

Restricted stock award 55,555 shares Common stock grant to director James LaCamp on August 11, 2026

Transaction price per share $0.00 per share Reported for the 55,555-share restricted stock award

Holdings after transaction 90,421 shares Total direct PetMed Express common stock held by LaCamp after the award

Vesting date August 11, 2027 Date when all granted restricted shares vest, subject to continued board service

Award plan year 2024 Granted under the PetMed Express, Inc. 2024 Omnibus Incentive Plan

Key Terms

restricted stock award, 2024 Omnibus Incentive Plan, continued service

3 terms

restricted stock award financial

"Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024"

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

2024 Omnibus Incentive Plan financial

"made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests"

continued service other

"vests as to all granted shares on August 11, 2027, subject to continued service"

FAQ

What did PetMed Express (PETS) director James LaCamp report in this Form 4?

Director James LaCamp55,555-share90,421 shares

Was the PetMed Express (PETS) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant/award acquisition55,555 restricted shares$0.00 per share

When do James LaCamp’s new restricted shares in PetMed Express (PETS) vest?

The 55,555 restricted sharesAugust 11, 2027

How many PetMed Express (PETS) shares does James LaCamp own after this award?

After the restricted stock award, James LaCamp directly holds 90,421 shares55,555 restricted shares

Under which plan was the PetMed Express (PETS) equity award to James LaCamp granted?

The 55,555-share restricted stock awardPetMed Express, Inc. 2024 Omnibus Incentive Plan

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:19 PM Accepted by SEC EDGAR 08/12/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person^*
LaCamp James
(Last) (First) (Middle)
C/O PETMED EXPRESS, INC.
420 S CONGRESS AVENUE
(Street)
DELRAY BEACH FLORIDA 33445
(City) (State) (Zip)
UNITED STATES
(Country) 2. Issuer Name and Ticker or Trading Symbol
PETMED EXPRESS INC [ PETS ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/11/2026 A 55,555⁽¹⁾ A $0 90,421 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Consists of a restricted stock award made pursuant to the PetMed Express, Inc. 2024 Omnibus Incentive Plan that vests as to all granted shares on August 11, 2027, subject to continued service on the Board of Directors.
Remarks:
/s/ James LaCamp 08/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/11/2026		A		55,555⁽¹⁾	A	$0	90,421	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

	/s/ James LaCamp	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)